LUNG CANCER: Crizotinib delivered objective response rates of 32% in a phase I study of NSCLC harbouring MET exon 14 skipping, most of whom (62%) had received prior therapy.

Web

Jan. 27, 2020

SCIENTIFIC

LUNG CANCER

Crizotinib delivered objective response rates of 32% in a phase I study of NSCLC harbouring MET exon 14 skipping, most of whom (62%) had received prior therapy.

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Drilon et al.  Nature Medicine volume 26, pages47–51(2020) 

Abstract

MET exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs)1. These alterations are associated with increased MET activity and preclinical sensitivity to MET inhibition2. Crizotinib is a multikinase inhibitor with potent activity against MET3. The antitumor activity and safety of crizotinib were assessed in 69 patients with advanced NSCLCs harboring MET exon 14 alterations.

Objective response rate was 32% (95% confidence interval (CI), 21–45) among 65 response-evaluable patients.

Objective responses were observed independent of the molecular heterogeneity that characterizes these cancers and did not vary by splice-site region and mutation type of the MET exon 14 alteration, concurrent increased MET copy number or the detection of a MET exon 14 alteration in circulating tumor DNA.

The median duration of response was 9.1 months (95% CI, 6.4–12.7).

The median progression-free survival was 7.3 months (95% CI, 5.4–9.1). MET exon 14 alteration defines a molecular subgroup of NSCLCs for which MET inhibition with crizotinib is active.

These results address an unmet need for targeted therapy in people with lung cancers with MET exon 14 alterations and adds to an expanding list of genomically driven therapies for oncogenic subsets of NSCLC